Cooperative Investigations, Clinical Studies, Conference Calls, New Drug Applications, and Strategies- Research Report on Insys, Integra, Bio-Reference, Raptor, and Ironwood
NEW YORK, December 17, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Insys Therapeutics, Inc. (NASDAQ: INSY), Integra Lifesciences Holdings Corporation (NASDAQ: IART), Bio-Reference Laboratories, Inc. (NASDAQ: BRLI), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Insys Therapeutics, Inc. Research Report
On December 12, 2013, Insys Therapeutics, Inc. (Insys) announced that the Company has received a subpoena from the Office of Inspector General of the Department of Health and Human Services (HHS)with regard to an investigation of potential violations that involve HHS programs. According to the Company, subpoena requests documents regarding its product Subsys®, including Insys' sales and marketing practices relating to the product. Insys stated that it plans to cooperate with the investigation. The Full Research Report on Insys Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/4c7f_INSY
Integra Lifesciences Holdings Corporation Research Report
On December 12, 2013, Integra Lifesciences Holdings Corporation (Integra) announced that its clinical study, Collagen Conduit Versus Microsurgical Neurorraphy: 2-Year Follow Up of a Prospective, Blinded Clinical and Electrophysiological Multicenter Randomized, Controlled Trial, has been published in the December issue of The Journal of Hand Surgery. Integra stated that the study concluded that entubulation nerve repair using the NeuraGen Nerve Guide is as effective a method of repairing mixed motor and sensory nerves as direct microsurgical suture. Simon Archibald, Chief Scientific Officer of Integra, commented, "Demonstrating the equivalent effectiveness of clinical entubulation repair of the major nerves of the forearm compared to the ''gold standard'’ of microsurgical repair is a significant milestone for this technology. This is the first report in the literature of a prospective, randomized, controlled study of functional recovery following the repair of major mixed motor and sensory nerves, using an approved and commercially available nerve conduit. We hope that this new information will aid the expansion and further adoption of the technique." The Full Research Report on Integra Lifesciences Holdings Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/c0a4_IART
Bio-Reference Laboratories, Inc. Research Report
On December 12, 2013, Bio-Reference Laboratories, Inc. (Bio-Reference) announced that it intends to release its Q4 FY2013 and full-year FY2013 earnings results on December 19, 2013, before the open of market trading. The Company stated that it will hold a conference call on the same day at 10:30 a.m. EST, which will be hosted by Marc D. Grodman M.D., President and CEO. Bio-Reference added that the live webcast of the call will be available at the Company's website, and will be archived for 30 days after the call.The Full Research Report on Bio-Reference Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/1f59_BRLI
Raptor Pharmaceutical Corp. Research Report
On December 10, 2013, Raptor Pharmaceutical Corp. (Raptor) announced that it has submitted an investigational new drug application (IND) to the US Food and Drug Administration (FDA) for the clinical development of RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. The Company informed that the RP103-MITO-001 trial is designed to evaluate the safety, tolerability and efficacy of RP103 in patients with genetically confirmed Leigh syndrome and other mitochondrial disorders. Raptor stated that the initiation of the clinical trial is planned for Q1 2014 and interim results are expected by the end of 2014. Patrice Rioux, M.D., Ph.D., Chief Medical Officer of Raptor, commented, "Our extensive understanding of the mechanisms of action of RP103 coupled with its potential tolerability, pharmacokinetics and pharmacodynamics is generating substantial rationale to conduct further studies in other orphan diseases. In addition to mitochondrial disorders including Leigh syndrome, we are already conducting clinical trials of RP103 in NAFLD and Huntington's disease, and we will consider additional indications as the science emerges."The Full Research Report on Raptor Pharmaceutical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/a001_RPTP
Ironwood Pharmaceuticals, Inc. Research Report
On December 12, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) reported that it will detail its strategy for establishing a leading gastrointestinal (GI) therapeutic companyduring its Investor Day in New York City. The Company stated that this strategy will leverage its strong development and commercial capabilities in addressing GI disorders and as its pharmacologic expertise in guanylatecyclase (GC) pathways.Peter Hecht, CEO of Ironwood, commented,"At Ironwood, we've had the privilege to successfully discover, develop and commercialize LINZESS, a medicine that is already helping hundreds of thousands of adult patients suffering from IBS-C or CIC. We will leverage our development and commercial expertise in an effort to address patient needs across the upper and lower gastrointestinal tract, and we will build on our deep pharmacologic expertise as we work to unlock value from our GC research platform, with a goal of advancing seven GI clinical development programs with multiple opportunities to generate proof of concept data over the next 24 months."Ironwood added that to execute its strategy, it will: Maximize LINZESS, Leverage strong commercial capabilities, Advance robust GI pipeline and guanylatecyclase (GC) research, and Prioritize investments in key value drivers. The Full Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/dbc4_IRWD
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented byNidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article